IP Library Granted Patent US 10,913,739
Granted Patent B2
US 10,913,739 · App. 16/633,335 · Granted Feb 9, 2021

Inhibitors of RORγ

Inventors: Robert J. Duguid (Glenmont, NY); John A. Grosso (Princeton Junction, NJ); Sergiy Krasutsky (Delmar, NY)
Assignee: Vitae Pharmaceuticals, LLC (121374)
C07D471/04C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,913,739
App. No.
16/633,335
Granted
Feb 9, 2021
Kind
B2
Abstract

The present disclosure relates to processes for the production of salts and crystalline forms of a compound having the formula.

Claims (9)

1. A method of converting crystalline Forms E, F, and G of a bis-hydrogen bromide salt having the following structural formula:

to crystalline Form D bis-hydrogen bromide salt comprising:

i) slurrying a composition comprising one or more of crystalline Forms E, F, and G in a mixture of isopropyl acetate/water; and

ii) separating the crystalline form D bis-hydrogen bromide salt from the mixture of isopropyl acetate/water.

2. The method of claim 1 , wherein the composition is slurried in a mixture of isopropyl acetate comprising 0.25% to 2.5% v/v of water.

3. The method of claim 1 , wherein the separation is done by filtration.

4. The method of claim 1 , wherein the amount of the one or more crystalline Forms E, F, and G present in the composition is greater than 90% by weight.

5. The method of claim 1 , wherein the bis-hydrogen bromide salt is of crystalline Form D characterized by at least three x-ray powder diffraction peaks at 2Θ angles selected from 14.24°, 15.24°, 15.90°, 18.54°, 18.82°, and 22.46°.

6. The method of claim 1 , wherein the bis-hydrogen bromide salt is of crystalline Form D characterized by at least three x-ray powder diffraction peaks at 2Θ angles selected from 14.24°, 15.24°, 15.90°, 18.54°, 18.82°, and 22.46°.

Assignments (4)
CHANGE OF NAME Recorded Jan 20, 2021
From: VITAE PHARMACEUTICALS, INC.
To: VITAE PHARMACEUTICALS, LLC
Reel/Frame 055042/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: KRASUTSKY, SERGIY; DUGUID, ROBERT J.
To: ALBANY MOLECULAR RESEARCH INC.
Reel/Frame 053872/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: ALBANY MOLECULAR RESEARCH INC.
To: VITAE PHARMACEUTICALS, LLC
Reel/Frame 053873/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: GROSSO, JOHN J.
To: VITAE PHARMACEUTICALS, LLC
Reel/Frame 053873/0425 →
Continuity (2)
Provisional Application 62536114 · Jul 24, 2017
Related Publication 20200148677A1 · May 14, 2020